Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis-Reference-Cited by-同舟云学术

Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis

Published:2016-06-10 Issue:3 Volume:47 Page:E120-E131
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Ogawa Eiichi¹,Furusyo Norihiro¹,Yamashita Naoki²,Kawano Akira³,Takahashi Kazuhiro⁴,Dohmen Kazufumi⁵,Nakamuta Makoto⁶,Satoh Takeaki⁷,Nomura Hideyuki⁸,Azuma Koichi⁹,Koyanagi Toshimasa¹⁰,Kotoh Kazuhiro¹¹,Shimoda Shinji¹²,Kajiwara Eiji¹³,Hayashi Jun¹⁴,

Affiliation:

1. Department of General Internal Medicine; Kyushu University Hospital; Fukuoka Japan

2. Department of Hepatology; Steel Memorial Yawata Hospital; Kitakyushu Japan

3. Department of Medicine; Kitakyushu Municipal Medical Center; Kitakyushu Japan

4. Department of Medicine; Hamanomachi Hospital; Fukuoka Japan

5. Department of Internal Medicine; Chihaya Hospital; Fukuoka Japan

6. Department of Gastroenterology, Kyushu Medical Center; National Hospital Organization; Fukuoka Japan

7. Center for Liver Disease; Kokura Medical Center, National Hospital Organization; Kitakyushu Japan

8. The Center for Liver Disease; Shin-Kokura Hospital; Kitakyushu Japan

9. Department of Medicine; Kyushu Central Hospital; Fukuoka Japan

10. Department of Medicine; Fukuoka City Hospital; Fukuoka Japan

11. Department of Medicine and Bioregulatory Science; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

12. Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

13. Kajiwara Clinic; Kitakyushu Japan

14. Kyushu General Internal Medicine Center; Haradoi Hospital; Fukuoka Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12738/fullpdf

Reference29 articles.

1. World Health Organization Hepatitis C key facts http://www.who.int/mediacentre/factsheets/fs164/en/

2. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study;Ryder;Gut,2004

3. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study;Ogawa;J Hepatol,2013

4. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

5. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study;Ogawa;J Gastroenterol Hepatol,2012

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Misunderstanding of hepatitis C virus (HCV) infection status by non–specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy;Journal of Infection and Chemotherapy;2022-09

2. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

3. Trends in hepatitis C virus‐associated mortality rates in Japan, 1998–2017;Journal of Gastroenterology and Hepatology;2021-05

4. Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan;Hepatology Research;2021-03

5. Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects;Internal Medicine;2020-01-15